Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets

Early Phase 1CompletedNCT03661892

University of Arizona14 enrolled

Overview

In patients with cancer induced bone pain, addition of Syndros will improve pain relief and decrease opioid requirement.

This a prospective single arm study enrolling patients with bone metastases from breast cancer who have been on opioid therapy for bone pain for at least 4 weeks. All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks). For patients who have side effects secondary to Sydnros, the dose will be decreased. Side effect assessment will be done by the research team 2 days after making the dose adjustment. If subject continues to have side effects, dose will be held until resolution of symptoms. If the study medicine is held for more than a week continuously, they will be taken off the study. In addition, they will have baseline blood and urine collected for biomarkers and also complete study related questionnaires (for secondary end points). They are also provided an opioid drug diary which they will take home during visit 1 to record their opioid pain medication use. Research staff will be calling patients on a weekly basis to reinforce opioid drug diary, assess for Syndros side effect, and adjust dose of Syndros. At the end of 8 weeks blood and urine is collected again and they will complete the study questionnaires.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bone Metastases Breast Cancer Pain

Interventions

SyndrosDRUG

As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below: Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Be capable of understanding the investigational nature of the study and all pertinent aspects of the study 2. Be capable of signing and providing written consent in accordance with institutional and federal guidelines 3. Have metastatic breast cancer with bone metastases 4. Be willing and able to comply with scheduled visits, treatment plan, and follow up with research staff 5. Age ≥ 21 years 6. Must be on opioid therapy for bone pain for at least 4 weeks Exclusion Criteria: 1. Have a known sensitivity to dronabinol or alcohol 2. Have a history of hypersensitivity reaction to alcohol 3. Using medical marijuana currently 4. Using Syndros for nausea or appetite stimulant 5. Receiving or have received disulfiram- or metronidazole- containing products within past 14 days 6. Are currently pregnant or are of child-bearing age and refuse to use adequate contraception 7. Have a history of psychiatric illness 8. Have a history of seizure disorders

Locations (1)

University of Arizona

Tucson, Arizona, United States

Outcomes

Primary Outcomes

Need for opiate pain medication

To evaluate change in opiate pain medication use after addition of Syndros.Hypothesis: Syndros will decrease the opiate usage by at least 20% at the end of 8wks. We will evaluate opioid pain medication use by using a drug diary and assessing the percentage change in opiate pain medication requirement at end of 8wks.

Time frame: Eight weeks

Secondary Outcomes

Change in pain

To evaluate change in pain using the Brief Pain Inventory tool. Hypothesis: Addition of Syndros will decrease pain intensity on the rating tool.

Time frame: Eight weeks

Change in quality of life

2\. To evaluate change in quality of life using the EORTC QLQ-C30 version 3.0 questionnaire. Hypothesis: Addition of Syndros will improve quality of life.

Time frame: Eight weeks

Change in bone modulation

To evaluate change in bone modulation by Syndros. Hypothesis: Syndros will decrease bone degradation there by decreasing serum and urine C-terminal telopeptide collagen cross-linker (CTX), N-terminal telopeptide (NTX) and increase osteocalcin.

Time frame: Eight weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.